It's been nothing but red since the annual report came out. The numbers for EPP in there were solid with decent growth but the real issue in my mind seems to be where (and importantly when) any diversification will come?!
Clinuvel have put forward and started things on a number of fronts and release plenty of communications but who could genuinely go through the information and progress to date and actually put any kind of priority order or solid timelines to this mix?
And how would anything sizeable be distributed to the patient population? If they get their Neuracthel all sorted, how will they be selling that and competing in a landscape where they don't have a total monopoly like EPP?
Ann: SCENESSE in Adolescent EPP Study, page-10
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.16 |
Change
0.090(0.60%) |
Mkt cap ! $759.1M | |||
| Open | High | Low | Value | Volume |
| $15.12 | $15.44 | $15.02 | $1.063M | 70.10K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 126 | $15.14 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.27 | 764 | 3 |
View Market Depth
| Last trade - 16.10pm 17/09/2024 (20 minute delay) ? |
| CUV (ASX) Chart |